Human ADME - Info Sheet

In 2026 we are continuing with the Day in the Life Of series, where we interview the people behind the medicines and find out what drives them, and how they go to where they are today. The series gives a personal insight into what it's like to work in the pharmaceutical industry and contribute to patients' health. 

Dedicated to adaptive early phase clinical trials and drug development, Quotient Sciences can help accelerate your molecule from first-in-human (FIH) to proof of concept (POC). We are focused on delivering the insight you need to design and deliver your clinical pharmacology program with confidence. Our fully integrated approach ensures seamless execution and high-quality results—delivered safely and rapidly

Quotient Sciences Featured as part of MMV Annual Report

Achieve your molecule’s next milestone with fit-forphase drug product formulations, backed by trusted data and the expertise you need to navigate the increasing complexity of small molecule and synthetic peptide therapeutics. Our adaptive approach assures scalable solutions for your molecule’s development—from preclinical through commercial drug product formulation, manufacturing, and supply.

Senior Director of Product Development, Robert Cornog, and Senior Director of Integrated Development, Brad Rowe, recently contributed to Contract Pharma's feature on HPAPI outsourcing, "Why HPAPI Outsourcing Is Surging", explaining the evolving demand, regulatory shifts, and analytical challenges shaping the HPAPI contract manufacturing market.

Translational Pharmaceutics® is a disruptive approach to drug development that helps you forge your own path to success and optimize every step by redefining the complementary, interconnected relationship between drug product design, supply and clinical testing. The Quotient Sciences Translational Pharmaceutics® platform integrates activities and adapts solutions to help you reach key milestones as quickly and efficiently as possible. A

After another successful year of bringing the pharmaceutical community together at CPHI Milan in October, hear direct from the exhibitors on why the event is so important for them and the industry as a whole. 

With decades of experience in developing palatable pediatric and patient-centric formulations, Quotient Sciences is actively engaged in the development of pediatric products on behalf of pharmaceutical and biotech customers.

Our innovative approach to formulation development is based on our proven track record in early clinical evaluation delivering phase-appropriate formulations across the product development pathway from preclinical to late-stage. With expertise in simple and complex dosage forms, our approach has been validated through our work with over 1,500 molecules at all stages of drug development.

At Quotient Sciences, we recognize that careful selection of appropriate delivery technologies is key to the design of successful MR formulations. We have extensive experience in using a wide variety of formulation technologies, having supported hundreds of modified-release formulations over the last three decades. Coupled with our agile and flexible approach to clinical and commercial manufacturing, this makes us the ideal partner to provide an end-to-end solution for the development of MR drug products.

Our Translational Pharmaceutics® approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

Quotient Sciences specialize in guiding drug products through the critical transition from late-stage optimization and registration batch manufacturing through to full commercial readiness. Our approach is built on rigorous science, regulatory alignment, risk-based focus, and operational flexibility.